Anticoagulant-induced intracerebral haemorrhage (ICH): risk factors and outcomes
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Anticoagulant-induced intracerebral haemorrhage (ICH): risk factors and outcomes. Hypertension. Fully referenced neurology checklist.
Risk factors
- Hypertension
- The risk may be higher with Rivaroxaban than with Dabigatran
Epidemiology
Locked: subscribe to see this section.
Outcomes
Locked: subscribe to see this section.
Related Neurochecklists
Locked: subscribe to see this section.
References
- Majeed A, Kim YK, Roberts RS, Holmstrom M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41:2860-2866.
- Toyoda K, Yasaka M, Uchiyima S, et al. Blood pressure levels and bleeding events during antithrombotic therapy: the bleeding with antithrombotic therapy (BAT) study. Stroke 2010; 41:1440-1444.
- Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176:1662-1671.
- Wu TY, Yassi N, Shah DG, et al. Simultaneous multiple intracerebral hemorrhages (SMICH). Stroke 2017; 48:581-586.
- Boulouis G, Morotti A, Pasi M, Goldstein JN, Gurol ME, Charidimou A. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis. JNNP 2017; pii: jnnp-2017-316631 (Epub ahead of print).
- And 2 more. Subscribe to see the full list
